Viekirax

ombitasvir / paritaprevir / ritonavir

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Viekirax. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Viekirax.

For practical information about using Viekirax, patients should read the package leaflet or contact their doctor or pharmacist.

What is Viekirax and what is it used for?

Viekirax is an antiviral medicine used in combination with other medicines to treat adults with chronic (long-term) hepatitis C, an infectious disease of liver caused by the hepatitis C virus.

It contains 3 active substances: ombitasvir, paritaprevir and ritonavir.

How is Viekirax used?

Viekirax can only be obtained with a prescription and treatment should be started and monitored by a doctor experienced in managing patients with chronic hepatitis C.

Viekirax is available as tablets containing 12.5 mg ombitasvir, 75 mg paritaprevir and 50 mg ritonavir. The recommended dose is two tablets taken once a day with food for 8, 12 or 24 weeks. Viekirax is always used in combination with other medicines for chronic hepatitis C, such as dasabuvir and ribavirin.

Several varieties (genotypes) of hepatitis C virus exist, and Viekirax is recommended for use in patients with virus of genotypes 1a, 1b and 4. The combination of medicines used and the duration of treatment will depend on the genotype of hepatitis C virus the patient is infected with, the nature of the liver problems they have, for example if they have liver cirrhosis (scarring) or their liver is not working properly, and whether they have received previous treatment. For further information, see the package leaflet.

How does Viekirax work?

The 3 active substances in Viekirax work in different ways: ombitasvir blocks the action of a protein in the hepatitis C virus called ‘NS5A’ and paritaprevir blocks the action of another protein called ‘NS3/4A’, both of which the virus needs to multiply. By blocking these proteins, the medicine prevents the hepatitis C virus from multiplying and infecting new cells.

The third active substance, ritonavir, does not act directly against hepatitis C virus but it blocks the action of an enzyme called CYP3A that breaks down paritaprevir. The inhibition of CYP3A slows the removal of paritaprevir from the body, allowing paritaprevir to act against the virus for longer.

What benefits of Viekirax have been shown in studies?

In 6 initial main studies involving around 2,300 patients infected with hepatitis C virus genotypes 1a or 1b, Viekirax in combination with dasabuvir was effective in clearing the virus from the blood. Between 96% and 100% of patients without liver scarring had their blood cleared of the virus after 12 weeks of treatment (with or without ribivarin). In patients with liver scarring, Viekirax treatment in combination with dasabuvir and ribavirin resulted in a clearance rate of between 93% and 100% after 24 weeks of treatment.

In a seventh study, patients with liver scarring but stable liver function (compensated cirrhosis) who had genotype 1b infection were treated with Exviera and Viekirax without ribavirin and 100% of patients (60 out of 60 patients) had their blood cleared of the virus.

An additional study showed Viekirax to be effective against genotype 4: when given with ribavirin, Viekirax cleared this genotype from the blood of all the 91 patients infected with it after 12 weeks. When Viekirax was given with only dasabuvir, the virus was cleared from the blood in 91% of the patients.

What are the risks associated with Viekirax?

The most common side effects with Viekirax in combination with dasabuvir and ribavirin (which may affect more than 1 in 10 people) are insomnia (difficulty sleeping), nausea, pruritus (itching), asthenia (weakness) and fatigue (tiredness). For the full list of all side effects, see the package leaflet.

Viekirax must not be used in patients with severe liver impairment and in women taking ethinylestradiol, an oestrogen found in hormonal contraceptives. It must also not be used together with medicines that affect the activity of certain enzymes that can raise or lower the levels of its active substances in the blood. For the full list of restrictions, see the package leaflet.

Why is Viekirax approved?

The European Medicines Agency noted that Viekirax in combination with other medicines is effective in clearing the hepatitis C virus genotypes 1a, 1b and 4, including in patients with liver scarring. Almost all the patients with these genotypes treated in studies had the virus cleared from their blood. The clearance rate was particularly high in patients infected with genotypes 1b and 4.

Regarding its safety, although there were some cases of raised liver enzymes in patients treated with Viekirax in combination with dasabuvir and ribavirin, side effects seen with this combination were generally well tolerated. The Agency therefore concluded that the benefits of Viekirax outweigh its risks and recommended that it be approved for use in the EU.

What measures are being taken to ensure the safe and effective use of Viekirax?

The company that markets Viekirax will carry out a study in patients who previously have had liver cancer to evaluate the risk of liver cancer returning after treatment with direct-acting antivirals such as Viekirax. This study is being carried out in light of data suggesting that patients treated with these medicines who have had liver cancer could be at risk of their cancer returning early.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Viekirax have also been included in the summary of product characteristics and the package leaflet.

Other information about Viekirax

The European Commission granted a marketing authorisation valid throughout the European Union for Viekirax on 15 January 2015.

For more information about treatment with Viekirax, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Viekirax : EPAR - Summary for the public BG = bălgarski 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public ES = español 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public CS = čeština 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public DA = dansk 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public DE = Deutsch 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public ET = eesti keel 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public EL = elliniká 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public EN = English 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public FR = français 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public IT = italiano 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public LV = latviešu valoda 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public LT = lietuvių kalba 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public HU = magyar 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public MT = Malti 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public NL = Nederlands 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public PL = polski 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public PT = português 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public RO = română 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public SK = slovenčina 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public SL = slovenščina 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public FI = suomi 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public SV = svenska 2015-03-09 2018-02-08
Viekirax : EPAR - Summary for the public HR = Hrvatski 2015-03-09 2018-02-08
Name Language First published Last updated
Viekirax : EPAR - Risk-management-plan summary (English only) 2015-03-09  

This EPAR was last updated on 08/02/2018 .

Authorisation details

Product details

Product details for Viekirax
NameViekirax
Agency product numberEMEA/H/C/003839
Active substance

ombitasvir / paritaprevir / ritonavir

International non-proprietary name (INN) or common name

ombitasvir / paritaprevir / ritonavir

Therapeutic area Hepatitis C, Chronic
Anatomical therapeutic chemical (ATC) code
Additional monitoring

This medicine is under additional monitoring. This means that it is being monitored even more intensively than other medicines. For more information, see medicines under additional monitoring.

Publication details

Publication details for Viekirax
Marketing-authorisation holder

AbbVie Ltd

Revision11
Date of issue of marketing authorisation valid throughout the European Union15/01/2015

Contact address:

AbbVie Ltd
Vanwall Business Park 
Vanwall Road 
Maidenhead
Berkshire SL6 4UB
United Kingdom

Product information

Product information

15/11/2017  Viekirax -EMEA/H/C/003839 -PSUSA/00010367/201701

Name Language First published Last updated
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27
Viekirax : EPAR - Product Information EN = English 2015-03-09 2017-11-27

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  
Viekirax : EPAR - All Authorised presentations EN = English 2015-03-09  

Pharmacotherapeutic group

Antivirals for systemic use

Therapeutic indication

Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.

For hepatitis C virus (HCV) genotype specific activity.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated
Viekirax : EPAR - Procedural steps taken and scientific information after authorisation EN = English 2015-09-28 2017-11-27
Viekirax-H-C-3839-A20-0018 : EPAR - Assessment Report - Variation EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-3839-A20-0018 : EPAR - Scientific Conclusion EN = English 2017-03-13  
Viekirax-H-C-PSUSA-00010367-201507 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation EN = English 2016-05-25  

Initial marketing-authorisation documents

Name Language First published Last updated
Viekirax : EPAR - Public assessment report EN = English 2015-03-09  
CHMP summary of positive opinion for Viekirax EN = English 2014-11-21